List of Excipients in Branded Drug INCRUSE ELLIPTA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	INCRUSE ELLIPTA	umeclidinium	0173-0873	LACTOSE MONOHYDRATE	2027-12-18
GlaxoSmithKline LLC	INCRUSE ELLIPTA	umeclidinium	0173-0873	MAGNESIUM STEARATE	2027-12-18

Last updated: August 2, 2026

Executive summary: INCRUSE ELLIPTA is a once-daily dry-powder inhaler containing umeclidinium bromide. Its excipient system is simple but technically important: lactose monohydrate acts as the carrier, while magnesium stearate supports powder-flow and moisture-control performance. The main commercial opportunity is not a conventional tablet-style excipient substitution. It is a device-compatible inhalation platform that can reproduce dose uniformity, aerosol performance, stability, and usability while managing lactose, milk-protein, and intellectual-property constraints.

INCRUSE ELLIPTA Excipient Strategy and Commercial Opportunities

INCRUSE ELLIPTA contains umeclidinium bromide in a preloaded ELLIPTA dry-powder inhaler. The labeled excipients are lactose monohydrate and magnesium stearate. The product is approved for once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, or COPD. It is not indicated for acute bronchospasm relief.[1]

What excipients are used in INCRUSE ELLIPTA?

The formulation uses a carrier-based dry-powder inhalation system.

Component	Function	Commercial relevance
Umeclidinium bromide	Long-acting muscarinic antagonist active ingredient	Low-dose, high-potency API requiring uniform dispersion
Lactose monohydrate	Bulk carrier and powder-processing aid	Controls blend dilution, dose uniformity, and aerodynamic delivery
Magnesium stearate	Lubricant and surface-modifying agent	Can improve powder flow, reduce cohesion, and influence drug detachment
ELLIPTA inhaler	Metering and delivery platform	Controls dose presentation, airflow resistance, emitted dose, and user handling

The US prescribing information identifies lactose monohydrate and magnesium stearate as the product’s inactive ingredients. The lactose contains milk proteins, creating a labeling and patient-screening issue for individuals with severe milk-protein allergy.[1]

The labeled strength is 62.5 micrograms of umeclidinium bromide per blister. The delivered dose is approximately 55 micrograms of umeclidinium from the mouthpiece under specified test conditions.[1]

How does the INCRUSE ELLIPTA excipient system work?

Lactose as the carrier

Umeclidinium is present at a very low dose relative to the total powder mass. Lactose provides a larger carrier surface onto which the micronized active ingredient can be distributed. The resulting blend must maintain adequate content uniformity across individual blisters and produce reliable drug detachment during inhalation.

The commercial value of lactose is tied to its physical properties rather than its pharmacological role. Particle-size distribution, crystallinity, surface roughness, moisture content, and supplier consistency can affect:

• Active-ingredient adhesion
• Blend segregation
• Fine-particle dose
• Emitted dose
• Dose uniformity
• Storage stability
• Device emptying

A generic developer cannot assume that pharmaceutical-grade lactose from one supplier is interchangeable with another supplier’s material. Small differences in carrier morphology can affect aerodynamic performance even when chemical specifications are similar.

Magnesium stearate as a surface modifier

Magnesium stearate can reduce interparticle cohesion and modify the interaction between micronized umeclidinium and lactose. In dry-powder inhalers, its concentration, mixing sequence, shear exposure, and distribution on particle surfaces can materially influence aerosolization.

Potential benefits include improved powder flow and more consistent drug detachment. Excessive surface coverage, however, may reduce drug-carrier adhesion too far, increase segregation, or alter emitted-dose behavior. The optimal concentration is therefore a formulation-development variable, not a simple excipient-compliance exercise.

The device is part of the formulation strategy

ELLIPTA is a multidose inhaler containing individually sealed powder doses. The formulation, foil blister structure, airflow path, dose mechanism, and mouthpiece operate as one delivery system. A product that matches the qualitative excipient list but uses a different inhaler may not be therapeutically or regulatorily substitutable without comparative performance and clinical evidence.

What formulation attributes must a generic INCRUSE ELLIPTA product reproduce?

A generic or follow-on product must establish pharmaceutical equivalence and bioequivalence through the applicable FDA pathway. For orally inhaled products, FDA evaluation places material weight on device performance, emitted dose, aerodynamic particle-size distribution, and comparative in vitro data.[2]

Attribute	Why it matters
Delivered dose uniformity	Determines whether each actuation provides the intended amount
Fine-particle dose	Correlates with the respirable fraction reaching the lower airways
Mass median aerodynamic diameter	Affects regional lung deposition
Geometric standard deviation	Indicates aerosol distribution width
Emitted dose	Measures powder leaving the device
Moisture uptake	Can change agglomeration and flow
Blend uniformity	Important because the API dose is extremely low
Device airflow resistance	Influences patient-generated inspiratory flow
Priming and dose counting	Affects usability and dose reliability
Stability after opening	Important for multidose storage and in-use life

The principal development challenge is usually not identifying a permissible excipient. It is controlling the interaction between micronized API, carrier lactose, magnesium stearate, blister packaging, and inhaler mechanics.

What commercial opportunities exist in the INCRUSE ELLIPTA excipient market?

1. Generic umeclidinium dry-powder inhalers

The largest opportunity is a generic product that delivers umeclidinium through an equivalent or legally distinct dry-powder inhaler. Competitive entry can target the active ingredient, the formulation, the device, or the full combination.

Potential value drivers include:

• Lower manufacturing cost
• Alternative inhaler architecture
• Improved dose counter
• Reduced residual powder
• More efficient blister production
• Improved supply-chain resilience
• Regional licensing of a finished inhaler
• Combination products using umeclidinium with vilanterol or fluticasone furoate

The commercial barrier is higher than for an oral generic because inhaler sameness and bioequivalence depend on the device and aerosol system.

2. Lactose-engineered carrier systems

A supplier able to provide tightly controlled inhalation-grade lactose can compete on performance rather than commodity price. Relevant product specifications include particle-size distribution, fines content, surface area, moisture, flowability, and microbial control.

Opportunities include:

• Narrower carrier particle-size distributions
• Engineered surface roughness
• Low-moisture lactose grades
• Improved lot-to-lot consistency
• Custom carrier grades for low-dose anticholinergics
• Regional supply qualification for dual sourcing

A carrier supplier with validated inhalation performance may obtain stronger commercial positioning than a general excipient supplier.

3. Lactose-free or low-lactose alternatives

INCRUSE ELLIPTA uses lactose containing trace milk proteins. A lactose-free formulation could address patient and prescriber concerns involving severe milk-protein allergy. It could also create a differentiated product for markets or hospitals that prefer non-lactose inhalation systems.

Possible alternatives include:

• Mannitol
• Trehalose
• Other inhalation-grade polyols
• Engineered crystalline carriers
• Carrier-free porous particles
• Spray-dried composite particles

The regulatory burden is substantial. A new carrier can change powder density, hygroscopicity, aerosolization, taste, throat deposition, and lung deposition. The commercial opportunity is strongest where the alternative provides a measurable clinical, safety, or usability benefit.

4. Magnesium-stearate optimization

Excipient suppliers and CDMOs can develop proprietary magnesium-stearate grades or processing methods for inhalation powders. Relevant variables include particle size, specific surface area, fatty-acid composition, moisture, and coating behavior.

Commercially useful development claims may relate to:

• Lower blend energy
• Faster powder processing
• Better emitted-dose consistency
• Reduced device retention
• Improved stability under humidity stress
• More robust performance across patient inhalation profiles

These claims require formulation-specific evidence. A generic magnesium stearate specification is unlikely to establish a durable competitive advantage by itself.

5. ELLIPTA-compatible contract manufacturing

The product’s multidose blister format creates an opportunity for CDMOs with capabilities in:

• Micronization
• Low-dose powder blending
• Foil blister forming and sealing
• Inhaler assembly
• Device filling
• Automated dose testing
• Extractables and leachables assessment
• Inhalation performance testing

The strongest CDMO position combines powder formulation, inhaler assembly, analytical testing, and regulatory support. Companies that only supply lactose or magnesium stearate have a narrower opportunity.

When does INCRUSE ELLIPTA lose exclusivity?

FDA approved INCRUSE ELLIPTA in 2014 under NDA 203975. The product’s five-year new-chemical-entity exclusivity period ended in 2019, subject to the precise regulatory calculation and any applicable patent protection.[1,3]

Exclusivity category	INCRUSE ELLIPTA position
New chemical entity exclusivity	Expired after the five-year period
Orphan-drug exclusivity	Not the principal exclusivity basis for COPD maintenance treatment
Pediatric exclusivity	Must be assessed from FDA records and applicable extensions
Patent exclusivity	Depends on listed patents and expiration dates
Device/formulation protection	May affect practical market entry even where NCE exclusivity has expired

Patent expiration cannot be inferred from the formulation label. A current Orange Book review is required because listed patents, pediatric extensions, terminal disclaimers, and litigation outcomes can alter the effective generic-entry date.[3]

What patents protect INCRUSE ELLIPTA?

Protection can arise from several layers:

1. Umeclidinium composition-of-matter patents.
2. Salt, polymorph, or crystalline-form patents.
3. Inhalable powder compositions.
4. Carrier and surface-modifier combinations.
5. Blister packaging and moisture-control systems.
6. Inhaler-device architecture.
7. Methods of treating COPD with once-daily umeclidinium.
8. Combination products containing umeclidinium and vilanterol or fluticasone furoate.

The excipient list alone does not establish infringement. A formulation using lactose and magnesium stearate may still avoid a specific claim if the patent requires a defined particle-size range, concentration, mixing process, device structure, or aerodynamic performance.

For freedom-to-operate work, the relevant sequence is:

• Review current Orange Book listings for the reference product.
• Identify issued US and foreign patent families.
• Map claim scope against API form, carrier grade, magnesium-stearate level, blister, and inhaler.
• Check terminal disclaimers and patent-term adjustments.
• Review Paragraph IV notices and district-court litigation.
• Separate formulation claims from device claims.
• Assess launch risk by jurisdiction.

Are Paragraph IV challenges likely for INCRUSE ELLIPTA?

A Paragraph IV challenge would require an ANDA applicant to certify that a listed patent is invalid, unenforceable, or not infringed. The applicant could also use a Paragraph III certification and wait for patent expiration.

Challenge route	Commercial effect
Paragraph III	Delayed launch until the relevant patent expires
Paragraph IV	Potential early launch, subject to litigation and 30-month-stay rules
Section viii statement	Carves out patented method-of-use language where permitted
Authorized generic	Can enter under the brand owner’s authorization without relying on a conventional Paragraph IV strategy

For INCRUSE ELLIPTA, the most important technical issues in a Paragraph IV dispute would likely involve inhaler equivalence, formulation claim construction, device claims, and whether the proposed product uses the claimed carrier or surface-treatment parameters.

What is the FDA regulatory status of INCRUSE ELLIPTA?

INCRUSE ELLIPTA is an FDA-approved inhaled maintenance product for COPD. It is a small-molecule drug-device combination, not a biologic.[1]

Biosimilar risk is therefore not applicable. The relevant competitive pathway is an ANDA or another abbreviated route for an orally inhaled product, not a 351(k) biosimilar application.

The label warns against use in milk-protein allergy and identifies common adverse reactions including nasopharyngitis, upper respiratory tract infection, cough, and arthralgia. The product is administered once daily and is not intended for acute symptom relief.[1]

How does INCRUSE ELLIPTA compare with competing COPD products?

Product	Active ingredient	Product type	Excipient or delivery implication
INCRUSE ELLIPTA	Umeclidinium	LAMA DPI	Lactose and magnesium stearate in ELLIPTA
SPIRIVA HANDIHALER	Tiotropium	LAMA capsule DPI	Capsule-based dose loading and different device workflow
TUDORZA PRESSAIR	Aclidinium	LAMA DPI	Breath-actuated device with distinct powder and airflow requirements
SEEBRI NEOHALER	Glycopyrrolate	LAMA capsule DPI	Capsule handling and device-specific delivery
ANORO ELLIPTA	Umeclidinium/vilanterol	LAMA/LABA DPI	Same broad ELLIPTA platform, combination-dose complexity
TRELEGY ELLIPTA	Fluticasone furoate/umeclidinium/vilanterol	ICS/LAMA/LABA DPI	Higher formulation and stability complexity

INCRUSE competes on once-daily dosing and device simplicity. It also competes against fixed-dose combinations that can reduce the need for separate inhalers. That commercial pressure limits the standalone growth opportunity for umeclidinium while increasing the value of ELLIPTA-compatible manufacturing and combination-product know-how.

What generic-entry risks exist for INCRUSE ELLIPTA?

The main risks are technical and legal.

Technical risks

• Failure to match fine-particle dose
• Dose segregation during filling
• Humidity-driven agglomeration
• Inconsistent lactose surface properties
• Inadequate device airflow equivalence
• Incorrect blister seal performance
• Poor dose-counter reliability
• Patient-to-patient variability in inspiratory flow

Legal risks

• Composition-of-matter patents
• Formulation patents
• Device patents
• Method-of-use patents
• Patent-term extensions
• Paragraph IV litigation
• Settlement restrictions
• Launch-at-risk exposure

Commercial risks

• COPD prescribing shifts toward dual and triple therapy
• Limited differentiation for a single-agent LAMA
• Brand loyalty to the ELLIPTA device
• High inhaler tooling and quality-control costs
• Pricing pressure after multiple generic entrants
• Limited value from excipient substitution without a visible product benefit

How strong is the INCRUSE ELLIPTA patent estate?

The estate should be assessed as layered rather than as a single patent asset. Composition-of-matter protection generally has greater exclusionary value than a narrow excipient claim. Device and formulation patents can still delay entry when they cover the specific inhaler architecture or aerosol-performance parameters required for a commercially viable substitute.

A practical strength assessment should score each family on:

Factor	High-value indicator
Claim breadth	Covers the active ingredient or essential delivery system
Remaining term	Extends beyond expected ANDA approval
Design-around difficulty	Requires a different device or clinically costly formulation
Validity profile	Strong written description and enablement support
Litigation history	Survived claim construction or validity challenge
Geographic scope	Protection in the US, Europe, Japan, and major COPD markets
Commercial relevance	Covers the actual marketed dose and device

Excipient patents are usually strongest when they claim a specific, reproducible performance relationship rather than merely naming lactose or magnesium stearate.

What licensing deals could create commercial value?

Potential licensing structures include:

• Umeclidinium API licensing to regional generic manufacturers
• ELLIPTA-compatible inhaler technology licensing
• Carrier-excipient supply agreements
• Contract filling and assembly arrangements
• Co-development of lactose-free inhalers
• Combination-product licenses involving umeclidinium and vilanterol
• Authorized-generic commercialization agreements
• Geographic rights for emerging markets

The most defensible licensing asset is a validated formulation-device package with comparative aerosol data, regulatory documentation, and scalable manufacturing. An excipient-only license has lower value unless it delivers a measurable improvement in stability, dose consistency, or patient usability.

What is the revenue exposure to generic entry?

INCRUSE revenue is exposed to both standalone LAMA substitution and therapeutic substitution into combination products. Generic entry can reduce price rapidly, but the erosion profile depends on:

• Number of approved ANDAs
• Timing of first generic launch
• Whether a 180-day exclusivity period applies
• Brand contracting strategy
• Payer preference
• Availability of umeclidinium combination products
• Physician dependence on the ELLIPTA device

The commercial opportunity is therefore stronger in platform supply, combination products, and device manufacturing than in an undifferentiated lactose-magnesium-stearate copy.

Key Takeaways

• INCRUSE ELLIPTA uses umeclidinium bromide, lactose monohydrate, and magnesium stearate in a multidose ELLIPTA dry-powder inhaler.
• Lactose provides the carrier matrix; magnesium stearate modifies powder flow and drug detachment.
• The key development challenge is reproducing aerosol performance and device behavior, not simply matching the inactive-ingredient list.
• Lactose-free and engineered-carrier formulations offer the clearest excipient-led differentiation.
• Generic competition is subject to API, formulation, device, method-of-use, and regulatory barriers.
• Biosimilar competition does not apply because umeclidinium is a small molecule.
• Commercial value is highest in validated inhaler platforms, specialty excipients, CDMO manufacturing, and umeclidinium combination products.
• Patent conclusions require current Orange Book and family-level claim analysis; formulation composition alone cannot establish freedom to operate.

FAQs

Can lactose in INCRUSE ELLIPTA cause problems for patients with milk allergy?

Yes. The product labeling warns that the lactose contains milk proteins and is contraindicated in patients with severe milk-protein allergy.[1]

Is magnesium stearate an active ingredient in INCRUSE ELLIPTA?

No. Magnesium stearate is an excipient used in the powder formulation. Its role relates to powder processing, flow, and aerosolization.

Could a generic INCRUSE product use mannitol instead of lactose?

Potentially, but the alternative carrier would require formulation, device, stability, and comparative performance development. It could also raise separate patent and regulatory issues.

Is INCRUSE ELLIPTA a biologic product?

No. INCRUSE ELLIPTA contains the small-molecule active ingredient umeclidinium bromide and is regulated through the drug approval framework rather than the biosimilar pathway.

Does matching the INCRUSE excipients guarantee generic approval?

No. A generic developer must establish the required pharmaceutical equivalence, device performance, aerosol characteristics, stability, and bioequivalence. Qualitative excipient matching is only one part of the development strategy.

References

1. U.S. Food and Drug Administration. (2023). INCRUSE ELLIPTA (umeclidinium bromide) inhalation powder: Prescribing information. GlaxoSmithKline.

2. U.S. Food and Drug Administration. (2023). Draft guidance on umeclidinium bromide inhalation powder. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm